Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Inventory changed +58.0% from the comparable as-filed period. The change ranks at the 100th percentile of 91 prior comparable changes. This reverses 11 consecutive comparable moves in the opposite direction.
Inventory / revenue changed +1065 basis points from the comparable as-filed period. The change ranks at the 88th percentile of 57 prior comparable changes. This reverses 7 consecutive comparable moves in the opposite direction.
Research & development changed +30.1% from the comparable as-filed period. The change ranks at the 94th percentile of 101 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.